nach oben

Current Infectious Disease Reports

Erschienen in:

01.10.2012 | Skin, Soft Tissue, Bone and Joint Infections (N Safdar, Section Editor)

From Ulcer to Infection: An Update on Clinical Practice and Adjunctive Treatments of Diabetic Foot Ulcers

verfasst von: C. Abad, N. Safdar

Erschienen in: Current Infectious Disease Reports | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Foot ulcers are a common complication of diabetes. A fifth of all individuals with diabetes develop a diabetic foot infection and are hospitalized at least once in their lifetime. Standard of care for treatment of diabetic foot ulcers and subsequent infection involves a multimodal, interdisciplinary team approach that includes wound care, systemic antimicrobials, and surgery. However, with the relatively poor outcome for chronic, longstanding ulcers and severe infections, recent research has focused on adjunctive therapies to promote wound healing and repair. This review summarizes the underlying pathology and classification of diabetic ulcers and focuses on recent advances that have important implications for the use of adjunctive therapy for diabetic foot infections.

Boulton AJ. The diabetic foot: a global view. Diabetes Metab Res Rev. 2000;16 Suppl 1:S2–5.PubMedCrossRef

Frykberg RG. Diabetic foot ulcers: current concepts. J Foot Ankle Surg. 1998;37:440–6.PubMedCrossRef

Lipsky BA, Peters EJ, Senneville E, et al. Expert opinion on the management of infections in the diabetic foot. Diabetes Metab Res Rev. 2012;28 Suppl 1:163–78.PubMedCrossRef

Pecoraro RE, Ahroni JH, Boyko EJ, Stensel VL. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes. 1991;40:1305–13.PubMedCrossRef

Reiber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus. A case-control study. Ann Intern Med. 1992;117:97–105.PubMed

Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999;22:157–62.PubMedCrossRef

Kumar S, Ashe HA, Parnell LN, et al. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabet Med. 1994;11:480–4.PubMedCrossRef

Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150–4.PubMedCrossRef

Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care. 1994;17:557–60.PubMedCrossRef

10.

Young MJ, Jones GC. Diabetic neuropathy: symptoms, signs and assessment. In: Boulton AJM, editor. Diabetic neuropathy. Lancashire: Marius Press; 1997. p. 41–61.

11.

Masson EA, Hay EM, Stockley I, Veves A, Betts RP, Boulton AJ. Abnormal foot pressures alone may not cause ulceration. Diabet Med. 1989;6:426–8.PubMedCrossRef

12.

Veves A, Murray HJ, Young MJ, Boulton AJ. The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study. Diabetologia. 1992;35:660–3.PubMedCrossRef

13.

Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care. 1990;13:513–21.PubMedCrossRef

14.

Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45:S1–S66.PubMedCrossRef

15.

Rothman KJ. Causes. Am J Epidemiol. 1976;141:90–5. 1995; discussion 89.

16.

Powlson AS, Coll AP. The treatment of diabetic foot infections. J Antimicrob Chemother;65 Suppl 3:iii3–9.

17.

Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. American Diabetes Association. Diabetes Care. 1999;22:1354–60.CrossRef

18.

Frykberg RG, Armstrong DG, Giurini J, et al. Diabetic foot disorders: a clinical practice guideline. American College of Foot and Ankle Surgeons. J Foot Ankle Surg. 2000;39:S1–S60.PubMedCrossRef

19.

Wagner FW. Supplement: algorithms of foot care. In: Levin ME, O’Neal LW, editors. The diabetic foot st. Louis: Mosby; 1983. p. 291–302.

20.

Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care. 1998;21:855–9.PubMedCrossRef

21.

Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician. 2002;66:1655–62.PubMed

22.

Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJ. A comparison of two diabetic foot ulcer classification systems: the Wagner and the University of Texas wound classification systems. Diabetes Care. 2001;24:84–8.PubMedCrossRef

23.

Terashi H, Kitano I, Tsuji Y. Total management of diabetic foot ulcerations--Kobe classification as a new classification of diabetic foot wounds. Keio J Med. 60:17–21.

24.

• Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39:885–910. This is a comprehensive review of diagnostic and therapeutic interventions for diabetic foot ulcers. PubMedCrossRef

25.

Gardner SE, Hillis SL, Frantz RA. Clinical signs of infection in diabetic foot ulcers with high microbial load. Biol Res Nurs. 2009;11:119–28.PubMedCrossRef

26.

Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007;45:2819–28.PubMedCrossRef

27.

El-Tahawy AT. Bacteriology of diabetic foot. Saudi Med J. 2000;21:344–7.PubMed

28.

Goldstein EJ, Citron DM, Nesbit CA. Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care. 1996;19:638–41.PubMedCrossRef

29.

Grayson ML. Diabetic foot infections. Antimicrobial therapy. Infect Dis Clin North Am. 1995;9:143–61.PubMed

30.

Jones EW, Edwards R, Finch R, Jeffcoate WJ. A microbiological study of diabetic foot lesions. Diabet Med. 1985;2:213–5.PubMedCrossRef

31.

Joseph WS, Axler DA. Microbiology and antimicrobial therapy of diabetic foot infections. Clin Podiatr Med Surg. 1990;7:467–81.PubMed

32.

Lipsky BA, Pecoraro RE, Wheat LJ. The diabetic foot. Soft tissue and bone infection. Infect Dis Clin North Am. 1990;4:409–32.PubMed

33.

Sims D, Keating SE, DeVincentis AF. Bacteriology of diabetic foot ulcers. J Foot Surg. 1984;23:149–51.PubMed

34.

Urbancic-Rovan V, Gubina M. Bacteria in superficial diabetic foot ulcers. Diabet Med. 2000;17:814–5.PubMedCrossRef

35.

Gerding DN. Foot infections in diabetic patients: the role of anaerobes. Clin Infect Dis. 1995;20 Suppl 2:S283–8.PubMedCrossRef

36.

Hunt JA. Foot infections in diabetes are rarely due to a single microorganism. Diabet Med. 1992;9:749–52.PubMedCrossRef

37.

Pathare NA, Bal A, Talvalkar GV, Antani DU. Diabetic foot infections: a study of microorganisms associated with the different Wagner grades. Indian J Pathol Microbiol. 1998;41:437–41.PubMed

38.

Sapico FL, Witte JL, Canawati HN, Montgomerie JZ, Bessman AN. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev Infect Dis. 1984;6 Suppl 1:S171–6.PubMedCrossRef

39.

Wheat LJ, Allen SD, Henry M, et al. Diabetic foot infections. Bacteriologic analysis. Arch Intern Med. 1986;146:1935–40.PubMedCrossRef

40.

Armstrong DG, Liswood PJ, Todd WF. William J. Stickel Bronze Award. Prevalence of mixed infections in the diabetic pedal wound. A retrospective review of 112 infections. J Am Podiatr Med Assoc. 1995;85:533–7.PubMed

41.

Candel Gonzalez FJ, Alramadan M, Matesanz M, et al. Infections in diabetic foot ulcers. Eur J Intern Med. 2003;14:341–3.PubMedCrossRef

42.

Diaz Colodrero G, Altclas J, Jasovich A, Mikaelian G, Fiks G, Caro E. Microbiology and conservative surgery of serious infections of the diabetic foot. Enferm Infecc Microbiol Clin. 1992;10:451–5.PubMed

43.

Ge Y, MacDonald D, Hait H, Lipsky B, Zasloff M, Holroyd K. Microbiological profile of infected diabetic foot ulcers. Diabet Med. 2002;19:1032–4.PubMedCrossRef

44.

Senneville E, Melliez H, Beltrand E, et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis. 2006;42:57–62.PubMedCrossRef

45.

Abdulrazak A, Bitar ZI, Al-Shamali AA, Mobasher LA. Bacteriological study of diabetic foot infections. J Diabetes Complications. 2005;19:138–41.PubMedCrossRef

46.

al-Arouj M, al-Nakhi A, Baraka A, Juma T, Johny M. Foot infections in diabetics: the antibiotic choice. Can J Surg. 1993;36:170–2.PubMed

47.

Zeillemaker AM, Veldkamp KE, van Kraaij MG, Hoekstra JB, Hoynck van Papendrecht AA, Diepersloot RJ. Piperacillin/tazobactam therapy for diabetic foot infection. Foot Ankle Int. 1998;19:169–72.PubMed

48.

O'Reilly D, Linden R, Fedorko L, et al. A prospective, double-blind, randomized, controlled clinical trial comparing standard wound care with adjunctive hyperbaric oxygen therapy (HBOT) to standard wound care only for the treatment of chronic, non-healing ulcers of the lower limb in patients with diabetes mellitus: a study protocol. Trials 12:69.

49.

Crouzet J, Lavigne JP, Richard JL and Sotto A. Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy. Int J Infect Dis;15:e601–10.

50.

Clay PG, Graham MR, Lindsey CC, Lamp KC, Freeman C, Glaros A. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males. Am J Geriatr Pharmacother. 2004;2:181–9.PubMedCrossRef

51.

Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents. 2005;26:357–65.PubMedCrossRef

52.

Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34:1460–8.PubMedCrossRef

53.

Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis. 2002;35:381–9.PubMedCrossRef

54.

Harkless L, Boghossian J, Pollak R, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect (Larchmt). 2005;6:27–40.CrossRef

55.

• Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. 2005;366:1695–703. This randomized controlled trial used rigorous definitions for infection in diabetic foot ulcers and found that ertapenem was noninferior to piperacillin-tazobactam as parenteral treatment for diabetic foot ulcers. PubMedCrossRef

56.

Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother. 2007;60:370–6.PubMedCrossRef

57.

Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis. 2008;47:1537–45.PubMedCrossRef

58.

Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis. 2004;38:17–24.PubMedCrossRef

59.

Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005;55:240–5.PubMedCrossRef

60.

Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46:647–55.PubMedCrossRef

61.

Saltoglu N, Dalkiran A, Tetiker T, et al. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect. 16:1252–7.

62.

Siami G, Christou N, Eiseman I, Tack KJ. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother. 2001;45:525–31.PubMedCrossRef

63.

Stevens DL. Teicoplanin for skin and soft tissue infections: an open study and a randomized, comparative trial versus cefazolin. J Infect Chemother. 1999;5:40–5.PubMedCrossRef

64.

Nelson S, Heyder AM, Stone J, et al. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis. 2000;182:970–3.PubMedCrossRef

65.

Sato N, Shimizu H. Granulocyte-colony stimulating factor improves an impaired bactericidal function in neutrophils from STZ-induced diabetic rats. Diabetes. 1993;42:470–3.PubMedCrossRef

66.

Dale DC, Liles WC, Summer WR, Nelson S. Review: granulocyte colony-stimulating factor–role and relationships in infectious diseases. J Infect Dis. 1995;172:1061–75.PubMedCrossRef

67.

Hartung T. Granulocyte colony-stimulating factor: its potential role in infectious disease. AIDS. 1999;13 Suppl 2:S3–9.PubMed

68.

Peck KR, Son DW, Song JH, Kim S, Oh MD, Choe KW. Enhanced neutrophil functions by recombinant human granulocyte colony-stimulating factor in diabetic patients with foot infections in vitro. J Korean Med Sci. 2001;16:39–44.PubMed

69.

Cruciani M, Lipsky BA, Mengoli C and de Lalla F. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database Syst Rev 2009;CD006810.

70.

de Lalla F, Pellizzer G, Strazzabosco M, et al. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother. 2001;45:1094–8.PubMedCrossRef

71.

Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet. 1997;350:855–9.PubMedCrossRef

72.

Viswanathan V, Mahesh U, Jayaraman M, Shina K, Ramachandram A. Beneficial role of granulocyte colony stimulating factor in foot infection in diabetic patients. J Assoc Physicians India. 2003;51:90–1.PubMed

73.

Yonem A, Cakir B, Guler S, Azal OO, Corakci A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab. 2001;3:332–7.PubMedCrossRef

74.

Kastenbauer T, Hornlein B, Sokol G, Irsigler K. Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers. Diabetologia. 2003;46:27–30.PubMed

75.

Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience. Ann Plast Surg. 1997;38:563–76. discussion 577.PubMedCrossRef

76.

Xie X, McGregor M, Dendukuri N. The clinical effectiveness of negative pressure wound therapy: a systematic review. J Wound Care 19:490–5.

77.

Bee TK, Croce MA, Magnotti LJ, et al. Temporary abdominal closure techniques: a prospective randomized trial comparing polyglactin 910 mesh and vacuum-assisted closure. J Trauma. 2008;65:337–42. discussion 342-4.PubMedCrossRef

78.

Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care. 2008;31:631–6.PubMedCrossRef

79.

Huang WS, Hsieh SC, Hsieh CS, Schoung JY, Huang T. Use of vacuum-assisted wound closure to manage limb wounds in patients suffering from acute necrotizing fasciitis. Asian J Surg. 2006;29:135–9.PubMedCrossRef

80.

Mody GN, Nirmal IA, Duraisamy S, Perakath B. A blinded, prospective, randomized controlled trial of topical negative pressure wound closure in India. Ostomy Wound Manage. 2008;54:36–46.PubMed

81.

Perez D, Bramkamp M, Exe C, von Ruden C and Ziegler A. Modern wound care for the poor: a randomized clinical trial comparing the vacuum system with conventional saline-soaked gauze dressings. Am J Surg. 199:14–20.

82.

Sepulveda G, Espindola M, Maureira M. et al [Negative-pressure wound therapy versus standard wound dressing in the treatment of diabetic foot amputation. A randomised controlled trial]. Cir Esp. 2009;86:171–7.PubMedCrossRef

83.

Akbari A, Moodi H, Ghiasi F, Sagheb HM, Rashidi H. Effects of vacuum-compression therapy on healing of diabetic foot ulcers: randomized controlled trial. J Rehabil Res Dev. 2007;44:631–6.PubMedCrossRef

84.

Ubbink DT, Westerbos SJ, Evans D, Land L and Vermeulen H. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev 2008:CD001898.

85.

Armstrong DG, Lavery LA. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. 2005;366:1704–10.PubMedCrossRef

86.

Eginton MT, Brown KR, Seabrook GR, Towne JB, Cambria RA. A prospective randomized evaluation of negative-pressure wound dressings for diabetic foot wounds. Ann Vasc Surg. 2003;17:645–9.PubMedCrossRef

87.

Etoz A, Ozgenel Y, Ozcan M. The use of negative pressure wound therapy on diabetic foot ulcers: a preliminary controlled trial. Wounds. 2004;16:264–9.

88.

McCallon SK, Knight CA, Valiulus JP, Cunningham MW, McCulloch JM, Farinas LP. Vacuum-assisted closure versus saline-moistened gauze in the healing of postoperative diabetic foot wounds. Ostomy Wound Manage. 2000;46:28–32. 34.PubMed

89.

Brown GL, Thomson PD, Mader JT, Hilton JG, Browne ME, Wells CH. Effects of hyperbaric oxygen upon S. aureus, Ps. aeruginosa and C. albicans. Aviat Space Environ Med. 1979;50:717–20.PubMed

90.

Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care. 1996;19:1338–43.PubMedCrossRef

91.

Marx RE, Ehler WJ, Tayapongsak P, Pierce LW. Relationship of oxygen dose to angiogenesis induction in irradiated tissue. Am J Surg. 1990;160:519–24.PubMedCrossRef

92.

Brismar K, Lind F, Kratz G. Dose-dependent hyperbaric oxygen stimulation of human fibroblast proliferation. Wound Repair Regen. 1997;5:147–50.PubMedCrossRef

93.

Reng JJ, Hussan MZ, Constant J, Hunt TK. Angiogenesis in wound healing. J Surg Pathol. 1998;3:1–7.

94.

Abidia A, Laden G, Kuhan G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg. 2003;25:513–8.PubMedCrossRef

95.

Doctor N, Pandya S, Supe A. Hyperbaric oxygen therapy in diabetic foot. J Postgrad Med. 1992;38:112–4. 111.PubMed

96.

Londahl M, Katzman P, Hammarlund C, Nilsson A and Landin-Olsson M. Relationship between ulcer healing after hyperbaric oxygen therapy and transcutaneous oximetry, toe blood pressure and ankle-brachial index in patients with diabetes and chronic foot ulcers. Diabetologia. 54:65–8.

97.

• Edwards J, Stapley S. Debridement of diabetic foot ulcers. Cochrane Database Syst Rev:CD003556. This review is a comprehensive synthesis of the literature on the myriad options available for debridement of diabetic foot ulcers.

98.

D’Hemecourt PA, Smiell JM, Karim MR. Sodium carboxymethyl cellulose aqueous-based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds. 1998;10:69–75.

99.

Jensen JL, Seeley J, Gillin B. Diabetic foot ulcerations. A controlled, randomized comparison of two moist wound healing protocols: Carrasyn Hydrogel Wound dressing and wet-to-moist saline gauze. Adv Wound Care. 1998;11:1–4.PubMed

100.

Markevich YO, McLeod-Roberts J, Mousley M and Melloy E. Maggot therapy for diabetic neuropathic foot wounds. In: Diabetologia: Proceedings of the 36th Annual Meeting of the European Association for the Study of Diabetes 2000;43: Suppl 1:A15.

101.

Piaggesi A, Schipani E, Campi F, et al. Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial. Diabet Med. 1998;15:412–7.PubMedCrossRef

102.

Vandeputte J, Gryson L. Diabetic foot infection controlled by immuno-modulating hydrogel containing 65%glycerine. Presentation of a clinical trial. 6th European Conference on Advances in Wound Managemen. Vol. 1997. Amsterdam, October 1996:50–3

103.

Whalley A, Boulton AJM, Harding K, Van Acker K and Capillas R. Performance characteristics and safety of purilon gel versus intrasite using biatain non-adhesive dressing as secondary dressing in the treatment of diabetic foot ulcers. 11th European Tissue Repair Society Annual Conference. Vol. 49. Cardiff, Wales, 2001.

104.

Jull AB, Rodgers A and Walker N. Honey as a topical treatment for wounds. Cochrane Database Syst Rev. 2008;CD005083.

105.

Shukrimi A, Sulaiman AR, Halim AY, Azril A. A comparative study between honey and povidone iodine as dressing solution for Wagner type II diabetic foot ulcers. Med J Malaysia. 2008;63:44–6.PubMed

106.

Moghazy AM, Shams ME, Adly OA, et al. The clinical and cost effectiveness of bee honey dressing in the treatment of diabetic foot ulcers. Diabetes Res Clin Pract. 89:276–81.

Titel: From Ulcer to Infection: An Update on Clinical Practice and Adjunctive Treatments of Diabetic Foot Ulcers
verfasst von: C. Abad
N. Safdar
Publikationsdatum: 01.10.2012
Verlag: Current Science Inc.
Erschienen in: Current Infectious Disease Reports / Ausgabe 5/2012
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-012-0283-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2012

Pediatric Sepsis: Preparing for the Future Against a Global Scourge

Immunoglobulins in Adult Sepsis and Septic Shock

Prevention of Surgical Site Infections in Bone and Joint Procedures

Septic Arthritis in the Native Joint

Chronic Osteomyelitis